Delving into the Latest Updates on SYNG Pharmaceuticals, Inc. with Synapse

概览

排名前五的药物类型	数量

化学药	1

排名前五的靶点	数量

Synucleins(突触核蛋白)	1

关联

1

项与 SYNG Pharmaceuticals, Inc. 相关的药物

SP-012

靶点

Synucleins

作用机制

突触核蛋白抑制剂

在研机构

SYNG Pharmaceuticals, Inc.

原研机构

SYNG Pharmaceuticals, Inc.

在研适应症

子宫内膜异位症

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 SYNG Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 SYNG Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 SYNG Pharmaceuticals, Inc. 相关的文献（医药）

2017-03-01·Fertility and Sterility2区 · 医学

Biomarkers in endometriosis: challenges and opportunities

2区 · 医学

Review

作者: Singh, Vinay ; Ahn, Soo Hyun ; Tayade, Chandrakant

Endometriosis is a debilitating gynecologic disease affecting millions of women across the world, with symptoms including dysmenorrhea, chronic pelvic pain, and infertility. Theorized to stem from the phenomenon of retrograde menstruation, the diagnosis of endometriosis is typically delayed by 8-10 years owing to misinterpretation of symptoms as common menstrual cramps in adolescent girls and young women. With increased incidence of endometriosis in young girls correlated with earlier menarche, the development of diagnostic biomarkers is imperative for diagnosing and treating women afflicted with endometriosis as early as we can. In the past few years, multiple reviews highlighted the list of potential diagnostic candidates in peritoneal fluid, blood, urine, and endometrial biopsies from endometriosis patients in different stages of disease and menstrual cycle. In this review, we explore the opportunities and challenges facing the field of diagnostic biomarkers for endometriosis. We highlight the importance of eutopic endometrium as a source of potential diagnostic biomarkers by looking at the expression levels of noncoding RNA in tissue as well as in blood. Finally, we discuss some of the challenges that hinder our efforts in validating candidate diagnostic biomarkers for endometriosis.

100 项与 SYNG Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 SYNG Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息